The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.

The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject.

A salt of a quinazoline derivative (N-[4-(3-chlorine-4-fluoroanilino)]-7-(3-morpholinepropanol)-6-(2-fluoroacrylamide)-quinazoline, the structure thereof is as represented by formula I). Compared with a known quinazoline derivative, the salt of the quinazoline derivative has one or more improved properties and at least has better water solubility, wherein a citrate, a benzene sulfonate, and an ethanedisulphonate thereof further have better crystallinity and are not easy to absorb moisture. ##STR00001##

A salt of a quinazoline derivative (N-[4-(3-chlorine-4-fluoroanilino)]-7-(3-morpholinepropanol)-6-(2-fluoroacrylamide)-quinazoline, the structure thereof is as represented by formula I). Compared with a known quinazoline derivative, the salt of the quinazoline derivative has one or more improved properties and at least has better water solubility, wherein a citrate, a benzene sulfonate, and an ethanedisulphonate thereof further have better crystallinity and are not easy to absorb moisture. ##STR00001##

Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.

The present invention relates to the compositions containing dicycloplatin, pharmaceutical use of the compositions in the treatment and/or prevention of pain, inflammation and virus-related diseases, and methods of preparing the compostions thereof.

Provided is a method for efficiently producing ferric citrate hydrate with high purity and various specific surface areas. The method for producing modified ferric citrate hydrate includes a step of bringing a solution containing water, citric acid, and ferric citrate as a material into contact with water-soluble organic solvent.

A method of manufacturing is provided for obtaining ferric citrate by a simple drying operation, the ferric citrate having a high purity, a high specific surface area, and a reduced water-soluble organic solvent content. The method of manufacturing ferric citrate, comprises a wet material of ferric citrate, containing the ferric citrate and a water-soluble organic solvent and having a water-soluble organic solvent content within the range of more than 0.3% by mass to 30.0% by mass or less, dried by bringing a gas containing water into contact.

Described herein is a liquid enzyme preparation containing

component (a): at least one salt according to general formula (I)

(R.sup.2).sub.3N.sup.+(CH.sub.2).sub.nC(R.sup.3)(R.sup.4)(OX).sub.mOC(O)R.sup.1 A.sup.(I) wherein n is selected from 1 to 12, m is selected from zero to 50, R.sup.1 is selected from the group consisting of methyl, ethyl, CH(OH)CH(OH)COOH, CH(OH)CH.sub.3, (E)-CHCHCOOH, (Z)CHCHCOOH, C.sub.6H.sub.5, para-HOC.sub.6H.sub.4, o,p-dihydroxyphenyl, and 3,4,5-triydroxyphenyl, R.sup.2 are same or different and selected from C.sub.1-C.sub.10-alkyl, phenyl, R.sup.3 and R.sup.4 are same or different and selected from hydrogen and C.sub.1-C.sub.4-alkyl, X is C.sub.2-C.sub.4-alkylen, and A.sup. is an inorganic or organic counteranion,
component (b): at least one enzyme selected from hydrolases (EC 3),
and
optionally component (c): at least one compound selected from enzyme stabilizers different from component (a), preservatives, and surfactants.